3613 (3613) Fair Value & Analysis

Healthcare · Market cap HK$5.4B

3 3613 3613 · HK

PriceHK$6.46

Fair ValueHK$10.44

Upside+61.6%

Quality63/100

Watch 3613 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$7.83 – HK$13.05

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −2.9% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$6.21 – HK$9.13 · fair‑value band HK$7.83 – HK$13.05 · the HK$6.46 price screens below the HK$10.44 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

3613 (3613) currently trades at HK$6.46, while our model-based Fair Value estimate is HK$10.44 — implying the stock looks roughly 61.6% undervalued today. We read business quality at 63/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 3613 generated revenue of HK$1.5B at a net margin of 26.3%. Revenue declined 20.6% year over year. It earns a return on equity of 9.7%. The balance sheet holds a net cash position of HK$2.1B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.5B

Revenue growth (YoY) -20.6%

Net margin 26.3%

Return on equity 9.7%

Free cash flow HK$827M FY2025

P/E ratio 13.8

More key figures

Operating margin 28.0%

EPS (TTM) HK$0.2800

Dividend yield 5.7%

EPS growth (YoY) -42.1%

Net cash HK$2.1B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

3613 reported revenue of HK$1.5B in FY2025 versus HK$1.6B in FY2021, a compound −0.7%/yr. Reported net income was HK$397M in FY2025, compounding −10.1%/yr from FY2021.

Revenue −0.7%/yr

FY21 HK$1.6B

FY22 HK$1.7B

FY23 HK$1.5B

FY24 HK$1.6B

FY25 HK$1.5B

Net income −10.1%/yr

FY21 HK$608M

FY22 HK$646M

FY23 HK$540M

FY24 HK$500M

FY25 HK$397M

Is 3613 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.01	¥26.59	-43%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$26.19	R$26.01	-1%
Hansoh Pharmaceutical Group 3692	HK$29.58	HK$18.75	-37%
Divi's Laboratories Limited DIVISLAB	₹6,788	₹2,035	-70%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 3613 (3613) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$10.44 versus a price of HK$6.46 — about +62% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 3613?

Our model-based fair value for 3613 is HK$10.44 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$6.46.

What is the quality score of 3613?

3613 has a Quality Score of 63/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 3613 (3613)?

3613 reported trailing-twelve-month revenue of about HK$1.5B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 3613?

The net profit margin of 3613 is about 26.3%, meaning it keeps roughly 26.3% of revenue as net income. Based on the latest reported figures.

Does 3613 pay a dividend?

3613 currently shows a dividend yield of about 5.72% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.